Localization of post-transplant lymphoproliferative disorders to the stomach might be associated with favorable outcome: a systematic review

Saudi J Kidney Dis Transpl. 2014 Mar;25(2):353-61. doi: 10.4103/1319-2442.128543.

Abstract

Gastric localization of post-transplant lymphoproliferative disorders (PTLDs) is very rare. In this study, we aimed to accumulate existing data in the current literature to reveal the clinical, histopathological and prognostic specificities associated with gastric PTLDs and to find the best treatment strategies in this patient population. A comprehensive search was conducted for the available data in the current literature using Pubmed and Google scholar search engines for reports on gastric PTLD in renal transplant recipients. Data of different studies were standardized and entered into a database and analyzed. No statistically significant difference was found between gastric and non-gastric PTLD. Gastric PTLD was relatively more prevalent in female patients (P = 0.08) and showed a trend toward better outcome (P = 0.1) and less metastasis (P = 0.07). Surgical intervention and rituximab therapy were associated with a more favorable outcome (17% mortality). Our study showed that organ transplant recipients having gastric PTLD develop metastasis less frequently and tend to have a relatively more favorable outcome. Prospective studies with larger patient populations are needed to confirm or modify our results.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Comorbidity
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / mortality*
  • Lymphoproliferative Disorders / therapy
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis
  • Rituximab
  • Stomach Diseases / mortality*
  • Stomach Diseases / therapy
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab